Analytical Data
-
Gene name
ST2
- Application
-
Alternative Names
ST2；DER4；ST2；T1；Interleukin-1 receptor-like 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01638
-
Expression Region
19-323aa
-
AA Sequence
KFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFAS GQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLM YSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVI DNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPA QNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQ EEGQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRL SRKNP
-
Molecular Weight
61 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ST2, a member of the interleukin (IL)-1 receptor family, has garnered significant interest in biomedical research due to its dual role in immune regulation and cardiovascular health. Initially identified as a receptor for IL-33, ST2 is now recognized for its involvement in various physiological and pathological processes, including allergic responses, asthma, heart failure, and atherosclerosis. The soluble form of ST2 (sST2) is released into circulation and has been shown to serve as a biomarker for endothelial dysfunction and myocardial stress. Elevated sST2 levels have been associated with poor outcomes in patients with heart failure and have potential implications in predicting disease progression. The recombinant ST2 protein is being explored for its therapeutic potential, as modulating ST2 signaling may provide new strategies for treating inflammatory and cardiovascular diseases. Understanding the molecular mechanisms of ST2 and its interactions in different contexts remains a key area of investigation, with the ultimate goal of leveraging ST2-targeted therapies to improve patient outcomes in various conditions.
